Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Comment by longterm56on Jun 22, 2020 8:45am
93 Views
Post# 31175729

RE:RE:RE:RE:Marsolais is very very excited

RE:RE:RE:RE:Marsolais is very very excitedEven if this SP reaction is a bit premature, a large spike like this will catch the attention of many, many traders ... so now would be a great time for additional news releases!!! Come on, TH!!!

  -LT

palinc2000 wrote:

This is his baby..I am sure that for him its represents more than just money...If this ever gets to market he will also be recognized and admired !
 

I think he may have been late to the Party with regards to the Nash opportunity but here he was very very early and might turn out to be a hero
Good for him

 

SPCEO1 wrote: TH clearly must think the data is legit because Marsolais is the only officer to earn his full bonus last year and the board also gave him a huge haul of options too. They clearly want him to stick around and see this work to its concludion.

 

palinc2000 wrote: Kudos to Marsilais! While this is still pre clinical data it seems to be almost progressing towards human trials at a much much faster pace than anticipated
IND will be submitted to FDA in 2020! 

 




Bullboard Posts